OCM
HAE icon

Olstein Capital Management’s Haemonetics HAE Stock Holding History

Olstein Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-14,400
Closed -$469K – 129
2014
Q1 		$469K Buy
+14,400
New +$550K 0.06% 129

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Olstein Capital Management's HAE Position: Q2 2014 in Review

Olstein Capital Management sold out of Haemonetics (HAE) in Q2 2014, closing a stake of 14,400 shares — an estimated $469K sold.

Olstein Capital Management first reported a position in HAE in Q1 2014 and held it in 1 quarter. The position peaked at $469K in Q1 2014. 175 funds tracked by Wall St. Rank hold HAE as of Q2 2014.

  • Olstein Capital Management reported no remaining Haemonetics position as of Q2 2014 after selling out during the quarter.
  • Olstein Capital Management sold 14,400 Haemonetics shares in Q2 2014, an estimated $469K.
  • Olstein Capital Management first reported a position in Haemonetics in Q1 2014 and held it in 1 quarter.
  • Olstein Capital Management's Haemonetics position peaked at $469K in Q1 2014.
  • 175 funds tracked by Wall St. Rank held Haemonetics as of Q2 2014.

Based on Olstein Capital Management's 13F filing for Q2 2014, filed 11 Aug 2014.